does tirzepatide cause gastritis Comparative safety and side effects of semaglutide and tirzepatide: Implications for clinical decision-making in obesity management Tirzepatide for Medical Weight Loss

In conclusion, the STEER study presented at ESC 2025 provides supportive real-world evidence that semaglutide 2.4 mg (Wegovy) may offer significant cardiovascular protection in people with obesity and established heart disease, even when compared against another active treatment such as tirzepatide

Liraglutide not only blocks insulin receptor and synaptic loss in the brain but also reverses memory impairment induced by AD-associated A oligomers, suggesting that GLP-1R activation may be used to protect brain insulin receptors and synapses in AD ( 3.2 Neuroinflammation AD and DM are significantly associated with neuroinflammatory mechanisms

On a semaglutide program specifically, sleep becomes even more critical

Regulatory Status: CagriSema (cagrilintide-semaglutide combination) NDA was submitted to the FDA in December 2025 for once-weekly treatment of overweight or obesity with weight-related comorbidities